⋮
0
0
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Showing live article 3043 of 3352 in channel 19681208
Article Details:
Author:
Language: Japanese
Channel Number: 19681208
Article Number: 3043
Date: March 12, 2024, 8:00 pm
URL: https://www.qlifepro.com/press/20240313-21-100226/ma-takeda-86/
GUID: https://www.qlifepro.com/press/?p=100226
←
$
X
X
NSFW?
Claim
0
X
Mark channel Not-Safe-For-Work?
cancel
confirm
NSFW Votes:
(
0
votes)
X
Are you the publisher?
Claim
or
contact us about
this channel.
X
0
X
RSSing.com
Search
Sharing:
Title:
URL:
Copy Share URL